Palbociclib receives NICE approval as combination therapy for advanced breast cancer

Written by Louis Gautier, Future Science Group

Newly released NICE guidance has led to palbociclib being made available for the treatment of certain advanced breast cancers with the Cancer Drugs Fund. The committee chose to approve the drug after hearing the views of patients prioritizing progression-free survival and alternative side-effects. The National Institute for Health and Care Excellence (NICE) recently released new guidance recommending palbociclib (Ibrance©) in combination with fulvestrant (Faslodex©) for treatment of certain types of breast cancer. Those with hormone receptor-positive, HER2-negative advanced breast cancer, and who have previously received endocrine therapy, will be offered the new combination in an attempt to expand treatment options...

To view this content, please register now for access

It's completely free